Short-term response to Adalimumab in childhood inflammatory bowel disease

Joshua D. Noe, Marian Pfefferkorn

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Adalimumab is effective for adults with moderate to severe Crohn's disease (CD). Data in children with inflammatory bowel disease (IBD) is sparse. We aim to evaluate pediatric IBD response to adalimumab. Methods: We conducted a retrospective chart review of pediatric IBD patients treated with adalimumab. We defined response as either a decrease in the disease activity index severity or remission after 3-6 months of treatment. Results: Ten patients were identified. Seven had CD, three had ulcerative colitis (UC). All had colonic disease and disease in either the esophagus, stomach, or duodenum. Eight patients initially responded to infliximab, 5 with CD and 3 with UC; 2 CD patients had incomplete data for evaluation. The mean and median times between initial infliximab and initial adalimumab were 29.5 and 24 months, respectively. Eight patients responded to adalimumab 40 mg or 80 mg biweekly, or 80 mg initial dose followed by 40 mg biweekly. The mean Pediatric Crohn's Disease Activity Index (PCDAI) in CD patients before and after adalimumab were 12 and 4.2, respectively (normal ≤10). The mean Lichtiger Colitis Activity Index (LCAI) in UC patients before and after adalimumab were 9 and 5.1, respectively (normal <10). Corticosteroids were weaned off in 4/7 patients at 1 to 10 months after initiation of adalimumab. One patient with CD and 1 patient with UC failed adalimumab, required surgery, and remained on corticosteroids. Conclusions: Adalimumab is useful in pediatric IBD patients who become intolerant of infliximab.

Original languageEnglish
Pages (from-to)1683-1687
Number of pages5
JournalInflammatory Bowel Diseases
Volume14
Issue number12
DOIs
StatePublished - 2008

Fingerprint

Inflammatory Bowel Diseases
Crohn Disease
Ulcerative Colitis
Pediatrics
Adrenal Cortex Hormones
Adalimumab
Colonic Diseases
Colitis
Duodenum
Esophagus
Stomach

Keywords

  • Adalimumab
  • Inflammatory bowel disease
  • Pediatrics

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Short-term response to Adalimumab in childhood inflammatory bowel disease. / Noe, Joshua D.; Pfefferkorn, Marian.

In: Inflammatory Bowel Diseases, Vol. 14, No. 12, 2008, p. 1683-1687.

Research output: Contribution to journalArticle

@article{495a852504a14c10a616b2709b6e221c,
title = "Short-term response to Adalimumab in childhood inflammatory bowel disease",
abstract = "Background: Adalimumab is effective for adults with moderate to severe Crohn's disease (CD). Data in children with inflammatory bowel disease (IBD) is sparse. We aim to evaluate pediatric IBD response to adalimumab. Methods: We conducted a retrospective chart review of pediatric IBD patients treated with adalimumab. We defined response as either a decrease in the disease activity index severity or remission after 3-6 months of treatment. Results: Ten patients were identified. Seven had CD, three had ulcerative colitis (UC). All had colonic disease and disease in either the esophagus, stomach, or duodenum. Eight patients initially responded to infliximab, 5 with CD and 3 with UC; 2 CD patients had incomplete data for evaluation. The mean and median times between initial infliximab and initial adalimumab were 29.5 and 24 months, respectively. Eight patients responded to adalimumab 40 mg or 80 mg biweekly, or 80 mg initial dose followed by 40 mg biweekly. The mean Pediatric Crohn's Disease Activity Index (PCDAI) in CD patients before and after adalimumab were 12 and 4.2, respectively (normal ≤10). The mean Lichtiger Colitis Activity Index (LCAI) in UC patients before and after adalimumab were 9 and 5.1, respectively (normal <10). Corticosteroids were weaned off in 4/7 patients at 1 to 10 months after initiation of adalimumab. One patient with CD and 1 patient with UC failed adalimumab, required surgery, and remained on corticosteroids. Conclusions: Adalimumab is useful in pediatric IBD patients who become intolerant of infliximab.",
keywords = "Adalimumab, Inflammatory bowel disease, Pediatrics",
author = "Noe, {Joshua D.} and Marian Pfefferkorn",
year = "2008",
doi = "10.1002/ibd.20534",
language = "English",
volume = "14",
pages = "1683--1687",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Short-term response to Adalimumab in childhood inflammatory bowel disease

AU - Noe, Joshua D.

AU - Pfefferkorn, Marian

PY - 2008

Y1 - 2008

N2 - Background: Adalimumab is effective for adults with moderate to severe Crohn's disease (CD). Data in children with inflammatory bowel disease (IBD) is sparse. We aim to evaluate pediatric IBD response to adalimumab. Methods: We conducted a retrospective chart review of pediatric IBD patients treated with adalimumab. We defined response as either a decrease in the disease activity index severity or remission after 3-6 months of treatment. Results: Ten patients were identified. Seven had CD, three had ulcerative colitis (UC). All had colonic disease and disease in either the esophagus, stomach, or duodenum. Eight patients initially responded to infliximab, 5 with CD and 3 with UC; 2 CD patients had incomplete data for evaluation. The mean and median times between initial infliximab and initial adalimumab were 29.5 and 24 months, respectively. Eight patients responded to adalimumab 40 mg or 80 mg biweekly, or 80 mg initial dose followed by 40 mg biweekly. The mean Pediatric Crohn's Disease Activity Index (PCDAI) in CD patients before and after adalimumab were 12 and 4.2, respectively (normal ≤10). The mean Lichtiger Colitis Activity Index (LCAI) in UC patients before and after adalimumab were 9 and 5.1, respectively (normal <10). Corticosteroids were weaned off in 4/7 patients at 1 to 10 months after initiation of adalimumab. One patient with CD and 1 patient with UC failed adalimumab, required surgery, and remained on corticosteroids. Conclusions: Adalimumab is useful in pediatric IBD patients who become intolerant of infliximab.

AB - Background: Adalimumab is effective for adults with moderate to severe Crohn's disease (CD). Data in children with inflammatory bowel disease (IBD) is sparse. We aim to evaluate pediatric IBD response to adalimumab. Methods: We conducted a retrospective chart review of pediatric IBD patients treated with adalimumab. We defined response as either a decrease in the disease activity index severity or remission after 3-6 months of treatment. Results: Ten patients were identified. Seven had CD, three had ulcerative colitis (UC). All had colonic disease and disease in either the esophagus, stomach, or duodenum. Eight patients initially responded to infliximab, 5 with CD and 3 with UC; 2 CD patients had incomplete data for evaluation. The mean and median times between initial infliximab and initial adalimumab were 29.5 and 24 months, respectively. Eight patients responded to adalimumab 40 mg or 80 mg biweekly, or 80 mg initial dose followed by 40 mg biweekly. The mean Pediatric Crohn's Disease Activity Index (PCDAI) in CD patients before and after adalimumab were 12 and 4.2, respectively (normal ≤10). The mean Lichtiger Colitis Activity Index (LCAI) in UC patients before and after adalimumab were 9 and 5.1, respectively (normal <10). Corticosteroids were weaned off in 4/7 patients at 1 to 10 months after initiation of adalimumab. One patient with CD and 1 patient with UC failed adalimumab, required surgery, and remained on corticosteroids. Conclusions: Adalimumab is useful in pediatric IBD patients who become intolerant of infliximab.

KW - Adalimumab

KW - Inflammatory bowel disease

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=59849102115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849102115&partnerID=8YFLogxK

U2 - 10.1002/ibd.20534

DO - 10.1002/ibd.20534

M3 - Article

C2 - 18618629

AN - SCOPUS:59849102115

VL - 14

SP - 1683

EP - 1687

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 12

ER -